RE:RE:RE:RE:RE:AstraZeneca posts ADC wins at SABCS in breast cancerDecember 09, 2022 - Astrazeneca goes head-to-head with Roche in breast cancer.
In its clinical sparring match with Kadcyla in metastatic breast cancer, Enhertu helped HER2-positive patients who'd received one prior therapy live "significantly longer," according to a SABCS press release.
https://www.fiercepharma.com/pharma/sabcs-astrazeneca-writes-next-chapter-breast-cancer-playbook-enhertu-head-head-win-versus
[This development perhaps adds further reasoning for Roche to quickly move to acquire ONCY]